All booth events at the exhibition are independently planned and organized by the participating exhibitors. The content of such events must comply with the laws and regulations of the Republic of China (Taiwan) or the host country/region of the exhibition. Events shall not involve or include any content deemed immoral, obscene, violent, gambling-related, infringing, or otherwise unlawful. The Organizer provides only the exhibition website platform and assumes no responsibility or guarantee regarding the content, quality, or legality of events conducted at individual booths. Participants are expected to evaluate and assume all associated risks. In the event of any improper events, the Organizer reserves the right to suspend such events.

The 1st Human Respiratory Organoid Culture System: Transforming Respiratory Vaccines and Therapeutic

2026/07/18 15:00-15:30
2026/07/19 15:00-15:30

Exhibitor：BIOMORGAN LIMITED

Booth No：N1108

Description

Limitations of outdated animal and cell‑line models hinder drug and vaccine development, driving high clinical failure rates. There is growing demand for human‑relevant, scalable models, especially for validating AI‑generated drug candidates. Our human respiratory organoid platform—“mini lung in a dish”—offers superior, clinically predictive models and enables cultivation of previously uncultivable viruses.

Notice

For Research Use Only

This Exhibitor's Event List

Asia’s First Integrated Organoid‑Based Precision Medicine Centre Driving Translational Impact

Cancer treatment still follows one‑size‑fits‑all guidelines, even though tumours vary widely in behaviour and drug response. Many patients lack actionable mutations, leaving clinicians without reliable guidance. Patient‑derived organoids (PDOs) grow a patient’s tumour into “mini‑tumours” for testing therapies in the lab, offering functional, patient‑specific insight to support more informed treatment decisions.

Event Time and Details